Corrigendum to “Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease” (Dig. Liver Dis. (2016) 48(4) (360–370))

In the last paragraph of Section 1, the sentence “VDZ is a monoclonal antibody blocking the α4β7 integrin which is selectively expressed by the vascular endothelium in the gastrointestinal tract [7]” should be replaced with: “VDZ is a monoclonal antibody blocking the α4β7 integrin which is selectively expressed by the activated GUT homing lymphocytes [7]”. Mariabeatrice Principi, Gastroenterology Section, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy, should have been listed in Appendix A (Members of the GIVI Study Group).